Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes
Investigational drugs in phase I and phase II clinical trials for thalassemia
LUSPATERCEPT INHIBITS pSMAD2/3 SIGNALING AND PROMOTES ERYTHROID MATURATION THROUGH A GATA1 DEPENDENT MECHANISM
Luspatercept
Luspatercept in the treatment of lower-risk myelodysplastic syndromes | Future Oncology
Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia - ScienceDirect
Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes
Impas Academy - Luspatercept is an erythroid maturation agent indicated for anemia in adults with beta thalassemia who require regular RBC transfusions. #drrashidsdrugupdates | Facebook
Development of luspatercept to treat ineffective erythropoiesis - ScienceDirect
Figure 1 | Evolving therapies for lower-risk myelodysplastic syndromes | SpringerLink
Smad2/3‐pathway ligand trap luspatercept enhances erythroid differentiation in murine β‐thalassaemia by increasing GATA‐1 availability - Martinez - 2020 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Mechanism of Action | Reblozyl® (luspatercept-aamt)
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΘΕΡΑΠΕΥΤ
Mechanism of action for select agents used or under investigation for... | Download Scientific Diagram
Luspatercept Approval
LUSPATERCEPT INHIBITS pSMAD2/3 SIGNALING AND PROMOTES ERYTHROID MATURATION THROUGH A GATA1 DEPENDENT MECHANISM
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes | Leukemia
Mechanisms of resistance to erythropoiesis-stimulating agents (ESAs). | Download Scientific Diagram
LUSPATERCEPT INHIBITS pSMAD2/3 SIGNALING AND PROMOTES ERYTHROID MATURATION THROUGH A GATA1 DEPENDENT MECHANISM
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis - ScienceDirect
2017 Clinical trials update in new treatments of β‐thalassemia - Makis - 2016 - American Journal of Hematology - Wiley Online Library
Managing Anemia in Lower-Risk MDS - ppt download
Smad2/3‐pathway ligand trap luspatercept enhances erythroid differentiation in murine β‐thalassaemia by increasing GATA‐1 availability - Martinez - 2020 - Journal of Cellular and Molecular Medicine - Wiley Online Library
The use of luspatercept for thalassemia in adults - ScienceDirect
Luspatercept (ACE-536): Potential therapy for Beta-Thalassemia
